transcode therapeutics is a boston based pre-clinical biopharmaceutical company focused on discovery, development and commercialization of a pipeline of innovative microrna (mirnas or mirs) therapeutics for treating metastatic disease.
Company profile
Ticker
RNAZ
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
811065054
RNAZ stock data
Latest filings (excl ownership)
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
23 Apr 24
8-K
TransCode Therapeutics Reports 2023 Results; Provides Business Update
5 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market
31 Jan 24
8-K
TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering
22 Jan 24
424B4
Prospectus supplement with pricing info
19 Jan 24
EFFECT
Notice of effectiveness
19 Jan 24
S-1/A
IPO registration (amended)
18 Jan 24
S-1/A
IPO registration (amended)
17 Jan 24
CORRESP
Correspondence with SEC
17 Jan 24
Transcripts
Latest ownership filings
SC 13G/A
Medarova Zdravka
15 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G
Lind Global Fund II LP
7 Dec 23
SC 13D/A
Dudley Robert Michael
10 Oct 23
4
Thomas A Fitzgerald
2 Oct 23
4
Robert Michael Dudley
2 Oct 23
SC 13G
TANG CAPITAL PARTNERS LP
26 Sep 23
4
Robert Michael Dudley
22 Jun 23
SC 13D/A
Dudley Robert Michael
16 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.45 mm | 7.45 mm | 7.45 mm | 7.45 mm | 7.45 mm | 7.45 mm |
Cash burn (monthly) | (no burn) | 111.47 k | 1.78 mm | 1.74 mm | 1.17 mm | 1.37 mm |
Cash used (since last report) | n/a | 763.52 k | 12.16 mm | 11.92 mm | 8.00 mm | 9.38 mm |
Cash remaining | n/a | 6.69 mm | -4.71 mm | -4.47 mm | -551.61 k | -1.93 mm |
Runway (months of cash) | n/a | 60.0 | -2.7 | -2.6 | -0.5 | -1.4 |
Institutional ownership, Q3 2022
57.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 1 |
Closed positions | 2 |
Increased positions | 1 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 5.52 mm |
Total shares | 3.33 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Hirschman Orin | 1.29 mm | $3.27 mm |
AIGH Capital Management | 1.29 mm | $1.42 mm |
Worth Venture Partners | 324.16 k | $357.00 k |
Vanguard | 200.12 k | $220.00 k |
Redmond Asset Management | 90.87 k | $100.00 k |
Geode Capital Management | 76.55 k | $84.00 k |
K.J. Harrison & Partners | 19.99 k | $22.00 k |
BLK Blackrock | 15.33 k | $17.00 k |
Shay Capital | 15.06 k | $17.00 k |
ACT Capital Management, LLLP | 6.50 k | $7.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Sep 23 | Robert Michael Dudley | Common Stock | Buy | Acquire P | No | No | 0.51 | 98,000 | 49.98 k | 180,262 |
28 Sep 23 | Thomas A Fitzgerald | Common Stock | Buy | Acquire P | No | No | 0.51 | 49,350 | 25.17 k | 56,318 |
21 Jun 23 | Robert Michael Dudley | Common Stock | Buy | Acquire P | No | No | 2.6515 | 12,000 | 31.82 k | 82,262 |
20 Jun 23 | Robert Michael Dudley | Common Stock | Buy | Acquire P | No | No | 2.5498 | 6,607 | 16.85 k | 70,262 |
9 Jun 23 | Robert Michael Dudley | Common Stock | Buy | Acquire P | No | No | 2.76 | 19,000 | 52.44 k | 61,155 |
9 Jun 23 | Robert Michael Dudley | Common Stock | Buy | Acquire P | No | No | 2.76 | 19,000 | 52.44 k | 912,114 |
News
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target
16 Apr 24
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $3 Price Target
3 Apr 24
Why Nextracker Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
1 Feb 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
31 Jan 24
Looking Into TransCode Therapeutics's Recent Short Interest
29 Jan 24
Press releases
TransCode Therapeutics Reports 2023 Results; Provides Business Update
3 Apr 24
Thinking about buying stock in Velo3D, Nova Lifestyle, indie Semiconductor, Citius Pharmaceuticals, or Transcode Therapeutics?
22 Mar 24
TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
6 Mar 24
Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market
31 Jan 24